Drugs.com New Drug ApplicationsOriginal article
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
BLA FilingRP1Positive
AI Analysis
Summary
Replimune announced FDA acceptance of its resubmitted Biologics License Application for RP1, an oncolytic immunotherapy for advanced melanoma. The acceptance of the resubmission represents a positive regulatory milestone for the clinical-stage biotechnology company.
Outcome Details
FDA accepted resubmission of Biologics License Application
Importance:7/10
Sentiment:
0.70
FDABLAOncolytic ImmunotherapyMelanomaRegulatory
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on June 26, 2026 9:07 PM